HELPING THE OTHERS REALIZE THE ADVANTAGES OF HOIPIN-1

MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate various intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major demo aims were To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis patients